Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK Capital for less than $30 million, in a deal that lets the beleaguered Somerville-based biotech avoid bankruptcy.
Recalls in the food and beverage industry due to contamination incidents can be catastrophic for a company. Not only do ...
The agreement, which also includes a team of biotech executives, will see Bluebird Bio’s stockholders receive $3.00 per share ...
There is a catch. If the private equity firms can boost sales of bluebird’s three gene therapies to $600 million—over any ...
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
Paris-based Spore.Bio, a startup that developed an artificial intelligence-driven method for detecting pathogens, said today ...
Passage Bio is outsourcing future analytical testing services in a cost-cutting move that will further cut its workforce, a ...
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.
Central Macedonia, a region on the northern mainland of Greece, is an important producer of food. It generates a quarter of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback